Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Med (Lausanne)
Autors principals: Mika, Thomas, Strate, Katharina, Ladigan, Swetlana, Aigner, Clemens, Schlegel, Uwe, Tischoff, Iris, Tischer-Zimmermann, Sabine, Eiz-Vesper, Britta, Maecker-Kolhoff, Britta, Schroers, Roland
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2019
Matèries:
Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930172/
https://ncbi.nlm.nih.gov/pubmed/31921871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00295
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars